The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

NCT05085561 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Cerebral Cavernous Malformation

Interventions

DRUG: REC-994
DRUG: Placebo

Sponsor

Recursion Pharmaceuticals Inc.